PMID- 23364255
OWN - NLM
STAT- MEDLINE
DCOM- 20131022
LR  - 20151119
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 18
IP  - 4
DP  - 2013 Jul
TI  - Effect of a single high loading dose of rosuvastatin on percutaneous coronary 
      intervention for acute coronary syndromes.
PG  - 327-33
LID - 10.1177/1074248412474346 [doi]
AB  - OBJECTIVES: A high loading dose of atorvastatin has been confirmed to reduce 
      postprocedural events in patients undergoing percutaneous coronary intervention 
      (PCI). In this study, we sought to investigate the protective effects of 
      rosuvastatin in patients with acute coronary syndromes (ACS) undergoing PCI and 
      to determine the effect of rosuvastatin pretreatment on the postprocedural levels 
      of high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and 
      monocyte chemotactic protein 1 (MCP-1). METHODS: A total of 125 patients with 
      non-ST-segment elevation ACS were randomized to pretreatment with rosuvastatin 
      (20 mg 2-4 hours before PCI [n = 62]) or placebo (n = 63). All the patients 
      received subsequent long-term rosuvastatin treatment (10 mg/d). The main end 
      point of the trial was the 30-day incidence of major adverse cardiac events 
      (death, myocardial infarction, or unplanned revascularization). Plasma levels of 
      hs-CRP, IL-6, and MCP-1 were detected before PCI and 6 hours, 24 hours, and 3 
      days after PCI. RESULTS: The primary end point occurred in 8.1% of the patients 
      in the rosuvastatin arm and 22.2% in the placebo arm (P < .01); this difference 
      was entirely attributed to a reduced incidence of myocardial infarction (8.1% vs 
      22.2%; P < .01). The postprocedural elevation in creatine kinase-MB and troponin 
      I was also significantly lower in the rosuvastatin group at 6 hours, 24 hours, 
      and 3 days. Plasma levels of hs-CRP, IL-6, and MCP-1 increased significantly 
      after PCI in both the rosuvastatin and control groups; however, the 
      postprocedural elevations in hs-CRP and IL-6 levels were significantly lower in 
      the rosuvastatin group than the control group. CONCLUSIONS: A single, high dose 
      (20 mg) of rosuvastatin prior to PCI reduces postprocedural myocardial injury in 
      patients with ACS, with a concomitant attenuation of the postprocedural increase 
      in hs-CRP and IL-6 levels.
FAU - Wang, Zhengzhong
AU  - Wang Z
AD  - Key Laboratory of Cardiovascular Remodeling and Function, Chinese Ministryof 
      Education and Chinese Ministry of Public Health, Qilu Hospital, Shandong 
      University, Jinan, Shandong, China.
FAU - Dai, Hongyan
AU  - Dai H
FAU - Xing, Mingqing
AU  - Xing M
FAU - Yu, Zhongxiang
AU  - Yu Z
FAU - Lin, Xianru
AU  - Lin X
FAU - Wang, Shoudong
AU  - Wang S
FAU - Zhang, Junyi
AU  - Zhang J
FAU - Hou, Fangjie
AU  - Hou F
FAU - Ma, Ying
AU  - Ma Y
FAU - Ren, Yongqiang
AU  - Ren Y
FAU - Tan, Kai
AU  - Tan K
FAU - Wang, Yanping
AU  - Wang Y
FAU - Ge, Zhiming
AU  - Ge Z
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130129
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Chemokine CCL2)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Interleukin-6)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Acute Coronary Syndrome/blood/*therapy
MH  - Aged
MH  - C-Reactive Protein/drug effects/metabolism
MH  - Chemokine CCL2/blood
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Fluorobenzenes/*administration & dosage
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage
MH  - Incidence
MH  - Interleukin-6/blood
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology/prevention & control
MH  - *Percutaneous Coronary Intervention
MH  - Postoperative Complications
MH  - Preoperative Care
MH  - Prospective Studies
MH  - Pyrimidines/*administration & dosage
MH  - Rosuvastatin Calcium
MH  - Sulfonamides/*administration & dosage
OTO - NOTNLM
OT  - high-sensitivity C-reactive protein
OT  - interleukin 6
OT  - monocyte chemotactic protein 1
OT  - non-ST segment elevation acute coronary syndrome
OT  - percutaneous coronary intervention
OT  - rosuvastatin
EDAT- 2013/02/01 06:00
MHDA- 2013/10/23 06:00
CRDT- 2013/02/01 06:00
PHST- 2013/02/01 06:00 [entrez]
PHST- 2013/02/01 06:00 [pubmed]
PHST- 2013/10/23 06:00 [medline]
AID - 1074248412474346 [pii]
AID - 10.1177/1074248412474346 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2013 Jul;18(4):327-33. doi: 
      10.1177/1074248412474346. Epub 2013 Jan 29.